Talaris Therapeutics Inc. is a late-clinical stage cell therapy company. It involved in developing a method of allogeneic hematopoietic stem cell transplantation with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases and certain severe non-malignant blood, immune and metabolic disorders. Talaris Therapeutics Inc. is based in BOSTON.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-73.89M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.66 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -41.82% |
| Return on Assets (Trailing 12 Months) | -39.37% |
| Current Ratio (Most Recent Fiscal Quarter) | 16.59 |
| Quick Ratio (Most Recent Fiscal Quarter) | 16.59 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $4.33 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.66 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 42.01M |
| Free Float | 35.08M |
| Market Capitalization | $106.30M |
| Average Volume (Last 20 Days) | 0.18M |
| Beta (Past 60 Months) | 2.27 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 16.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 65.43% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |